Researchers have revealed that artificial intelligence has succeeded in creating two new types of antibiotics that may kill drug -resistant gonorrhea and MRSA resistant to methyline, after they have proven their effectiveness in laboratory tests and animals.
Corn level design
A team from the Massachusetts Institute of Technology (MIT) designed the two slopes of a seed atom using artificial intelligence, stressing that this technique may open the “second golden age” to discover antibiotics. Scientists have made clear that antibiotics face a crisis due to bacteria resistance, as drug -resistant infection causes more than a million deaths annually.
Challenges of deficiency of antibiotics
Excessive use of antibiotics contributed to the development of bacteria to resist their effects, while the world has suffered from the development of new drugs for decades. In the previous, the researchers have used artificial intelligence to examine thousands of known chemicals, but the MIT team went further using obstetric intelligence to design new antibiotics from scratch.
Examine millions of vehicles
The study was published in Cell, where the researchers analyzed 36 million compounds, including unveiled vehicles yet. Artificial intelligence was trained on known chemical structures and data about their impact on the growth of different types of bacteria, which enabled it to understand the effect of the molecular structure on bacteria.
Two design strategies
The team used two approaches: The first started to search for small chemical parts from 8 to 19 atoms to build the antibiotic, and the second gave artificial intelligence complete freedom of the design. Any vehicles that resemble current anti -antibiotics were excluded or seemed inappropriate medical or toxic to humans.
Successful laboratory and animal tests
After manufacturing the initial models, it was tested on the bacteria in the laboratory and in the mice, and this resulted in two new and promising antibiotics. Professor James Collins from MIT said: “Artificial intelligence can enable us to design new molecules quickly at a lower cost, giving us a superiority in our battle against super bacteria.”
The need for years of development
Despite the promising results, the two drugs still need a year or two of the development before starting clinical tests on humans, which is a long process to ensure safety and effectiveness.
